SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Irène Joliot-Curie Synthetic CCD

PatientIrène Joliot-Curie
Date of birth1968-09-12
IdentifiersMRN HR-RB003-SYN; SSN (made up) 000-03-8841
Document date2026-11-01
AuthorSolène Marchand-Ellis, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit for two months of tiredness, bruising and bleeding gums: blood count with blasts on the smear, and urgent hematology referral. Concerns: She has been worn out for two months, bruises easily and her gums bleed; she suspects her blood and wants to know at once; She knows the long-term effects of radiation on the bone marrow from her own field and from her mother's illness, and wants her exposure history taken seriously. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycleOnce daily on days 1 to 7 of each 28-day cycleSubcutaneous route2026-09-28activeS
Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole)Ramp-up, then two tablets daily with the 50 mg tablet, with food and waterOral route2026-09-28 to 2026-10-19completedS
Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day)One tablet daily from day 3, with food and waterOral route2026-09-28 to 2026-10-19completedS
Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic300 mg twice on day 1, then 300 mg once daily with foodOral route2026-09-28activeS
Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxisOne tablet twice dailyOral route2026-09-28activeS
Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5One tablet daily during profound neutropeniaOral route2026-09-28 to 2026-10-30completedS
Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1One tablet dailyOral route2026-09-28 to 2026-10-19completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route2026-10-08activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g once daily, held for loose stoolsOral route2026-10-08activeS
Sennosides 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route2026-10-08 to 2026-10-19completedS
Potassium chloride 20 mEq extended-release tablet, one tablet twice daily for three daysOne tablet twice daily for three daysOral route2026-10-08 to 2026-10-11completedS
Venetoclax 10 mg oral tablet, cycle 2: two tablets daily with the 50 mg tablet (70 mg a day, the dose with posaconazole) on days 1 to 21Two tablets daily on days 1 to 21, with food and waterOral route2026-10-30activeS
Venetoclax 50 mg oral tablet, cycle 2: one tablet daily with two 10 mg tablets (70 mg a day) on days 1 to 21One tablet daily on days 1 to 21, with food and waterOral route2026-10-30activeS

Procedures

ProcedureDatesStatusEvidence
Bone marrow aspiration and trephine biopsy, posterior iliac crest, with flow cytometry, cytogenetics and molecular testing2026-09-16 to 2026-09-16completedS
Transfusion of one unit of irradiated, leukoreduced red cells for symptomatic anemia (hemoglobin 7.1 g/dL)2026-09-16 to 2026-09-16completedS
Chest X-ray, posteroanterior and lateral2026-09-16 to 2026-09-16completedS
Pulmonary function tests with diffusing capacity2026-09-28 to 2026-09-28completedS
Transthoracic echocardiogram2026-09-28 to 2026-09-28completedS
Twelve-lead ECG before posaconazole2026-09-28 to 2026-09-28completedS
Bone marrow aspiration and biopsy on day 22 of cycle 1, with flow cytometry for measurable residual disease2026-10-19 to 2026-10-19completedS
Transfusion of one unit of irradiated, leukoreduced red cells (hemoglobin 7.4 g/dL with tiredness)2026-10-08 to 2026-10-08completedS
Transfusion of one dose of irradiated platelets (count 9 x10^3/uL)2026-10-08 to 2026-10-08completedS
Twelve-lead ECG before an antiemetic2026-10-08 to 2026-10-08completedS
Advance care planning conversation, about 30 minutes2026-10-26 to 2026-10-26completedS

Immunizations

DateVaccineStatusEvidence
2026-10-26Influenza vaccine, inactivated, this seasoncompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1914Worked as a nurse radiographer with X-ray machines in field hospitals in the First World War, the start of her occupational radiation exposureD (CLM-0002)
1944Tuberculosis, with a long recovery in Switzerland during the Second World WarD (CLM-0008)
1946A capsule of polonium exploded on her laboratory benchD (CLM-0010)
1950Health visibly declining from shortly after this yearD (CLM-0013)

Family History

RelativeConditionAge at deathEvidence
motherA physicist who also worked with radioactive materials; died of aplastic anemia that her physician attributed to bone marrow injury from long exposure to radiationD (CLM-0016)

Health Concerns

ConcernStatusEvidence
She has been worn out for two months, bruises easily and her gums bleed; she suspects her blood and wants to know at onceactiveS
She knows the long-term effects of radiation on the bone marrow from her own field and from her mother's illness, and wants her exposure history taken seriouslyactiveS

Assessment

Most recent measures: Leukocytes [#/volume] in Blood by Automated count 0.7 on 2026-10-08; Neutrophils [#/volume] in Blood by Automated count 0.1 on 2026-10-08; Hemoglobin [Mass/volume] in Blood 7.4 on 2026-10-08; MCV [Entitic mean volume] in Red Blood Cells by Automated count 104 on 2026-09-14; Platelets [#/volume] in Blood by Automated count 9 on 2026-10-08; Blasts/Leukocytes in Blood by Manual count 0 on 2026-10-30; Sodium [Moles/volume] in Serum or Plasma 137 on 2026-10-08; Potassium [Moles/volume] in Serum or Plasma 3.3 on 2026-10-08; Creatinine [Mass/volume] in Serum or Plasma 0.84 on 2026-10-08; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 84 on 2026-10-30; Calcium [Mass/volume] in Serum or Plasma 9.1 on 2026-09-28; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 on 2026-10-30; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 2026-09-28; Albumin [Mass/volume] in Serum or Plasma 3.9 on 2026-09-14; Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma 196 on 2026-10-19; Urate [Mass/volume] in Serum or Plasma 5.8 on 2026-09-28; ECOG Performance Status score 1 on 2026-10-30; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 2026-10-30; Blasts/cells in Bone marrow 3 on 2026-10-19; INR in Platelet poor plasma by Coagulation assay 1.1 on 2026-09-16; Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay 310 on 2026-09-16; Phosphate [Mass/volume] in Serum or Plasma 3.6 on 2026-09-28; Diffusion capacity.carbon monoxide/Predicted 58 on 2026-09-28; FEV1 measured/predicted 76 on 2026-09-28; Left ventricular Ejection fraction 62 on 2026-09-28; Q-T interval corrected 446 on 2026-10-08; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 2026-10-26; Magnesium [Mass/volume] in Serum or Plasma 1.8 on 2026-10-08; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-10-26; Total score [AUDIT-C] 1 on 2026-10-26 [S]

Strengths and supports: Supports: a close family, long-standing colleagues, and work she believes in [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review bookedresolvedconfirmed D61.818S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D).
Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemiaactiveconfirmed C92.00S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented.
Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years agoactiveconfirmed Z57.1S — Synthetic modern coding of her documented occupational exposure.
Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active diseaseactiveconfirmed Z86.11S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic.
Moderately reduced lung gas transfer (DLCO 58 percent of predicted, FEV1 76 percent) from old tuberculous scarring of the right upper lobe; with performance status 2, it makes her unfit for intensive inductionactiveconfirmed R94.2S — Synthetic finding on pre-treatment testing.
Nausea with vomiting and constipation on day 11 of cycle 1 of azacitidine with venetoclax, without fever, with mild low potassium; managed as an outpatient; resolvedresolvedconfirmed R11.2S — Synthetic treatment side effect; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-14Leukocytes [#/volume] in Blood by Automated count2.110*3/uL4-11 10*3/uLLowS
2026-09-14Neutrophils [#/volume] in Blood by Automated count0.610*3/uL1.5-7.5 10*3/uLLowS
2026-09-14Hemoglobin [Mass/volume] in Blood8.4g/dL12-15.5 g/dLLowS
2026-09-14MCV [Entitic mean volume] in Red Blood Cells by Automated count104fL80-100 fLHighS
2026-09-14Platelets [#/volume] in Blood by Automated count3810*3/uL150-400 10*3/uLLowS
2026-09-14Blasts/Leukocytes in Blood by Manual count12%None seen normallyHighS
2026-09-14Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-09-14Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
2026-09-14Creatinine [Mass/volume] in Serum or Plasma0.78mg/dL0.57-1 mg/dLNormalS
2026-09-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M88mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-14Calcium [Mass/volume] in Serum or Plasma9.2mg/dL8.6-10.3 mg/dLNormalS
2026-09-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-09-14Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-09-14Albumin [Mass/volume] in Serum or Plasma3.9g/dL3.5-5 g/dLNormalS
2026-09-14Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma412U/L140-280 U/LHighS
2026-09-14Urate [Mass/volume] in Serum or Plasma6.4mg/dL2.6-6 mg/dLHighS
2026-09-14ECOG Performance Status score1{score}S
2026-09-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-09-16Leukocytes [#/volume] in Blood by Automated count1.910*3/uL4-11 10*3/uLLowS
2026-09-16Neutrophils [#/volume] in Blood by Automated count0.510*3/uL1.5-7.5 10*3/uLLowS
2026-09-16Hemoglobin [Mass/volume] in Blood7.1g/dL12-15.5 g/dLLowS
2026-09-16Platelets [#/volume] in Blood by Automated count2210*3/uL150-400 10*3/uLLowS
2026-09-16Blasts/Leukocytes in Blood by Manual count14%None seen normallyHighS
2026-09-16Blasts/cells in Bone marrow34%Below 5% normally; 20% or more defines AMLHighS
2026-09-16INR in Platelet poor plasma by Coagulation assay1.1{INR}0.8-1.2NormalS
2026-09-16Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay310mg/dL200-400 mg/dLNormalS
2026-09-28Leukocytes [#/volume] in Blood by Automated count1.610*3/uL4-11 10*3/uLLowS
2026-09-28Neutrophils [#/volume] in Blood by Automated count0.410*3/uL1.5-7.5 10*3/uLLowS
2026-09-28Hemoglobin [Mass/volume] in Blood8.6g/dL12-15.5 g/dLLowS
2026-09-28Platelets [#/volume] in Blood by Automated count1810*3/uL150-400 10*3/uLLowS
2026-09-28Blasts/Leukocytes in Blood by Manual count16%None seen normallyHighS
2026-09-28Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-09-28Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
2026-09-28Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.57-1 mg/dLNormalS
2026-09-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M85mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-28Calcium [Mass/volume] in Serum or Plasma9.1mg/dL8.6-10.3 mg/dLNormalS
2026-09-28Phosphate [Mass/volume] in Serum or Plasma3.6mg/dL2.5-4.5 mg/dLNormalS
2026-09-28Urate [Mass/volume] in Serum or Plasma5.8mg/dL2.6-6 mg/dLNormalS
2026-09-28Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma448U/L140-280 U/LHighS
2026-09-28Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
2026-09-28Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
2026-09-28Diffusion capacity.carbon monoxide/Predicted58%80% of predicted or moreLowS
2026-09-28FEV1 measured/predicted76%>=80%LowS
2026-09-28Left ventricular Ejection fraction62%55-70%NormalS
2026-09-28Q-T interval corrected428msAbove 460 ms is prolonged in womenNormalS
2026-09-28ECOG Performance Status score2{score}S
2026-09-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
2026-09-28Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
2026-10-19Leukocytes [#/volume] in Blood by Automated count0.610*3/uL4-11 10*3/uLLowS
2026-10-19Neutrophils [#/volume] in Blood by Automated count0.210*3/uL1.5-7.5 10*3/uLLowS
2026-10-19Hemoglobin [Mass/volume] in Blood8.9g/dL12-15.5 g/dLLowS
2026-10-19Platelets [#/volume] in Blood by Automated count3110*3/uL150-400 10*3/uLLowS
2026-10-19Blasts/Leukocytes in Blood by Manual count0%None seen normallyNormalS
2026-10-19Blasts/cells in Bone marrow3%Below 5% normally; 20% or more defines AMLNormalS
2026-10-19Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-10-19Potassium [Moles/volume] in Serum or Plasma3.9mmol/L3.5-5.1 mmol/LNormalS
2026-10-19Creatinine [Mass/volume] in Serum or Plasma0.79mg/dL0.57-1 mg/dLNormalS
2026-10-19Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M87mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-19Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma196U/L140-280 U/LNormalS
2026-10-19Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-35 U/LNormalS
2026-10-30Leukocytes [#/volume] in Blood by Automated count2.210*3/uL4-11 10*3/uLLowS
2026-10-30Neutrophils [#/volume] in Blood by Automated count0.910*3/uL1.5-7.5 10*3/uLLowS
2026-10-30Hemoglobin [Mass/volume] in Blood9.6g/dL12-15.5 g/dLLowS
2026-10-30Platelets [#/volume] in Blood by Automated count8810*3/uL150-400 10*3/uLLowS
2026-10-30Blasts/Leukocytes in Blood by Manual count0%None seen normallyNormalS
2026-10-30Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-30Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-10-30Creatinine [Mass/volume] in Serum or Plasma0.81mg/dL0.57-1 mg/dLNormalS
2026-10-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-30Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-35 U/LNormalS
2026-10-30ECOG Performance Status score1{score}S
2026-10-30Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-10-08Leukocytes [#/volume] in Blood by Automated count0.710*3/uL4-11 10*3/uLLowS
2026-10-08Neutrophils [#/volume] in Blood by Automated count0.110*3/uL1.5-7.5 10*3/uLLowS
2026-10-08Hemoglobin [Mass/volume] in Blood7.4g/dL12-15.5 g/dLLowS
2026-10-08Platelets [#/volume] in Blood by Automated count910*3/uL150-400 10*3/uLLowS
2026-10-08Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-10-08Potassium [Moles/volume] in Serum or Plasma3.3mmol/L3.5-5.1 mmol/LLowS
2026-10-08Creatinine [Mass/volume] in Serum or Plasma0.84mg/dL0.57-1 mg/dLNormalS
2026-10-08Magnesium [Mass/volume] in Serum or Plasma1.8mg/dL1.7-2.2 mg/dLNormalS
2026-10-08Q-T interval corrected446msAbove 460 ms is prolonged in womenNormalS
2026-10-26Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-10-26Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S
2026-10-26Total score [AUDIT-C]1{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-09-14Body height163cmS
2026-09-14Body weight54kgS
2026-09-14Body mass index (BMI) [Ratio]20.3kg/m2S
2026-09-14Systolic blood pressure118mm[Hg]S
2026-09-14Diastolic blood pressure70mm[Hg]S
2026-09-14Heart rate96/minS
2026-09-14Respiratory rate16/minS
2026-09-14Body temperature37.2CelS
2026-09-14Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-16Body height163cmS
2026-09-16Body weight53.8kgS
2026-09-16Body mass index (BMI) [Ratio]20.2kg/m2S
2026-09-16Systolic blood pressure114mm[Hg]S
2026-09-16Diastolic blood pressure68mm[Hg]S
2026-09-16Heart rate100/minS
2026-09-16Respiratory rate18/minS
2026-09-16Body temperature37.3CelS
2026-09-16Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-09-28Body height163cmS
2026-09-28Body weight53.5kgS
2026-09-28Body mass index (BMI) [Ratio]20.1kg/m2S
2026-09-28Systolic blood pressure116mm[Hg]S
2026-09-28Diastolic blood pressure70mm[Hg]S
2026-09-28Heart rate92/minS
2026-09-28Respiratory rate16/minS
2026-09-28Body temperature36.9CelS
2026-09-28Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-10-19Body height163cmS
2026-10-19Body weight52.8kgS
2026-10-19Body mass index (BMI) [Ratio]19.9kg/m2S
2026-10-19Systolic blood pressure110mm[Hg]S
2026-10-19Diastolic blood pressure66mm[Hg]S
2026-10-19Heart rate90/minS
2026-10-19Respiratory rate16/minS
2026-10-19Body temperature37CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-10-30Body height163cmS
2026-10-30Body weight53.6kgS
2026-10-30Body mass index (BMI) [Ratio]20.2kg/m2S
2026-10-30Systolic blood pressure118mm[Hg]S
2026-10-30Diastolic blood pressure72mm[Hg]S
2026-10-30Heart rate84/minS
2026-10-30Respiratory rate16/minS
2026-10-30Body temperature36.8CelS
2026-10-30Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-08Body height163cmS
2026-10-08Body weight52.4kgS
2026-10-08Body mass index (BMI) [Ratio]19.7kg/m2S
2026-10-08Systolic blood pressure106mm[Hg]S
2026-10-08Diastolic blood pressure64mm[Hg]S
2026-10-08Heart rate98/minS
2026-10-08Respiratory rate16/minS
2026-10-08Body temperature37.2CelS
2026-10-08Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-10-26Body height163cmS
2026-10-26Body weight53.2kgS
2026-10-26Body mass index (BMI) [Ratio]20kg/m2S
2026-10-26Systolic blood pressure116mm[Hg]S
2026-10-26Diastolic blood pressure70mm[Hg]S
2026-10-26Heart rate86/minS
2026-10-26Respiratory rate16/minS
2026-10-26Body temperature36.8CelS
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-09-14New patient visit for two months of tiredness, bruising and bleeding gums: blood count with blasts on the smear, and urgent hematology referralfinishedS
2026-09-16Hematology consultation and bone marrow biopsy: diagnosis of acute myeloid leukemia, transfusion, and pre-treatment work-upfinishedS
2026-09-28Genetic results, classification and risk, fitness for treatment, early palliative care, and day 1 of azacitidine with venetoclaxfinishedS
2026-10-19Day 22 of cycle 1: bone marrow response, transfusion and infection review, and stopping venetoclax for count recoveryfinishedS
2026-10-30Count recovery and response assessment; cycle 2; transplant evaluation; occupational dose recordsfinishedS
2026-10-08Same-day sick visit for nausea, vomiting and constipation during cycle 1finishedS
2026-10-26Periodic adult preventive visit during AML therapyfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Urgent evaluation of pancytopenia with blasts on the smear: peripheral smear review, comprehensive metabolic panel, LDH and uric acid today; coagulation tests at the hematology visit; no aspirin or anti-inflammatory drugs; go to the emergency department at once for a temperature of 38.0 °C or more, bleeding that does not stop, or new confusion or headachecompletedGL-NCCN-AML-2026S
Urgent hematology/oncology consultation within two days for suspected acute leukemia: bone marrow biopsy, classification and treatment plancompletedGL-NCCN-AML-2026S
Occupational health history: her work with X-rays, polonium and other sources over about four decades, and the sealed-source accident in her laboratory, documented; written request to the employer's radiation safety office for her dosimetry and bioassay records, which the employer must keep and must furnish on requestcompletedGL-NRC-19-13, GL-OSHA-1910-1096S
Transfusion support: irradiated, leukoreduced products; red cells one unit at a time for hemoglobin below 7 to 8 g/dL or symptoms; platelets for a count below 10 x10^3/uL, for bleeding, or before procedures that need themcompletedGL-AABB-RBC-2023, GL-AABB-PLT-2015, GL-NCCN-AML-2026S
Pre-treatment work-up: HLA typing for a future transplant, hepatitis B, hepatitis C and HIV testing, chest X-ray because of past tuberculosis, echocardiogram, lung function tests with diffusing capacity, and a dental checkcompletedGL-NCCN-AML-2026, GL-ASCO-HBV-2020S
Induction with azacitidine 75 mg/m2 on days 1 to 7 and venetoclax ramped up to 70 mg daily (the dose for use with posaconazole), in 28-day cycles; admitted for the ramp-up with tumor lysis monitoring, allopurinol and fluids; bone marrow at day 21 to 28, holding venetoclax if blasts are below 5% until counts recover; later cycles with 21 days of venetoclaxcompletedGL-NCCN-AML-2026, GL-ELN-AML-2022, GL-VIALE-A-2020S
Infection prevention: posaconazole, acyclovir, and levofloxacin while neutrophils are below 0.5; a written fever plan (temperature of 38.0 °C or more: go to the emergency department for antibiotics within one hour); hand hygiene and food safetycompletedGL-NCCN-INFX-2026, GL-ASCO-IDSA-FN-2018S
Specialist palliative care alongside treatment from the first cycle: symptoms, prognosis in plain numbers, her goals and values, and advance care planning, reviewed at every visitcompletedGL-ASCO-PALL-2024, GL-NCCN-AML-2026S
Allogeneic stem cell transplant evaluation by the transplant center from the first cycle: an unrelated donor search from her HLA typing, reduced-intensity conditioning if she reaches remission, and measurable residual disease monitoringcompletedGL-NCCN-AML-2026, GL-ELN-AML-2022S
Nausea and constipation during cycle 1: ondansetron as needed after a normal QTc, with no other QT-prolonging antiemetic; polyethylene glycol and senna by mouth, no rectal medicines while neutropenic; potassium replaced; red cells and platelets given; venetoclax continued with foodcompletedGL-ASCO-ANTIEMETIC-2020, GL-NCCN-AML-2026, GL-AABB-PLT-2015S

Goals

GoalTargetStatusOutcomeProvenance
Diagnosis, classification and a treatment decision within two weeks of the first visit2026-09-28completedMarrow two days after the first visit; genetics back and treatment started on day 14S
Complete cycle 1 without tumor lysis, invasive fungal infection, or bleeding2026-10-30completedNo tumor lysis; no fever or fungal infection; no bleeding beyond bruising; one outpatient visit for nauseaS
Remission on the response assessment after cycle 1 (ELN 2022 complete remission, or complete remission with partial hematologic recovery)2026-10-30completedDay-22 marrow blasts 3%; at day 33 neutrophils 0.9 and platelets 88: complete remission with partial hematologic recovery, measurable residual disease positiveS
Her own goals and values recorded and her symptoms controlled with the palliative care team from the first cycle2026-09-28completedSeen by the palliative care team on day 1; goals recorded; symptoms reviewed at every visitS
Her occupational dose records obtained and the exposure history documented2026-10-30activeRecords requested in writing from the employer's radiation safety office; history documentedS

Functional Status

Mental Status